Literature DB >> 19364857

Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice.

Baohong Ji1, Aurélie Chauffour, Alexandra Aubry, Jérome Robert, Murad Ibrahim, Vincent Jarlier.   

Abstract

Because of operational limitations, a significant proportion of the health centers at the peripheral level are able to provide treatment to Buruli ulcer patients with the combination rifampin (rifampicin)-streptomycin (RIF-STR) only five times weekly (5/7) instead of seven times weekly (7/7), as recommended. The objective of this experiment is to assess the impacts of various dosing frequencies of the combination on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice. The results demonstrate that the bactericidal activities did not differ significantly among five dosing frequencies of the combination, ranging from seven times to twice weekly, whereas the sterilizing activities differed widely. RIF-STR 7/7 was the only regimen that was able to sterilize the infection after 4 to 8 weeks of treatment; the sterilizing activities associated with reduced dosing frequencies were significantly diminished, and 8 weeks of 5/7 administration yielded a relapse rate greater than the generally accepted level of 5%. We recommend that the duration of treatment with 5/7 administration be prolonged beyond 8 weeks and that additional experiments with mice be carried out, with sufficient statistical power to compare the relapse rates of M. ulcerans infection between 8 weeks of 7/7 administration and 10 and 12 weeks of 5/7 administration of RIF-STR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19364857      PMCID: PMC2704658          DOI: 10.1128/AAC.00011-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors:  Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

2.  Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.

Authors:  S Etuaful; B Carbonnelle; J Grosset; S Lucas; C Horsfield; R Phillips; M Evans; D Ofori-Adjei; E Klustse; J Owusu-Boateng; G K Amedofu; P Awuah; E Ampadu; G Amofah; K Asiedu; M Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Association of specific mutations in katG, rpoB, rpsL and rrs genes with spoligotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Russia.

Authors:  M Y Lipin; V N Stepanshina; I G Shemyakin; T M Shinnick
Journal:  Clin Microbiol Infect       Date:  2007-04-02       Impact factor: 8.067

4.  Characterisation of rpsL, rrs and embB mutations associated with streptomycin and ethambutol resistance in Mycobacterium tuberculosis.

Authors:  Tatjana Tracevska; Inta Jansone; Anda Nodieva; Olgerts Marga; Girts Skenders; Viesturs Baumanis
Journal:  Res Microbiol       Date:  2004-12       Impact factor: 3.992

5.  Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin.

Authors:  Sébastien Lefrançois; Jérôme Robert; Aurélie Chauffour; Baohong Ji; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

6.  Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria.

Authors:  I Guillemin; V Jarlier; E Cambau
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

7.  Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.

Authors:  Baohong Ji; Aurélie Chauffour; Jérôme Robert; Sébastien Lefrançois; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).

Authors:  Annick Chauty; Marie-Françoise Ardant; Ambroise Adeye; Hélène Euverte; Augustin Guédénon; Christian Johnson; Jacques Aubry; Eric Nuermberger; Jacques Grosset
Journal:  Antimicrob Agents Chemother       Date:  2007-05-25       Impact factor: 5.191

10.  Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.

Authors:  Baohong Ji; Aurélie Chauffour; Jérome Robert; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

View more
  5 in total

1.  Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.

Authors:  Marie-Thérèse Ruf; Daniela Schütte; Aurélie Chauffour; Vincent Jarlier; Baohong Ji; Gerd Pluschke
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Mycobacterium liflandii outbreak in a research colony of Xenopus (Silurana) tropicalis frogs.

Authors:  J J Fremont-Rahl; C Ek; H R Williamson; P L C Small; J G Fox; S Muthupalani
Journal:  Vet Pathol       Date:  2010-11-29       Impact factor: 2.221

Review 3.  Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review.

Authors:  Marius Zambou Vouking; Violette Claire Tamo; Carine Nouboudem Tadenfok
Journal:  Pan Afr Med J       Date:  2013-08-29

4.  Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.

Authors:  Deepak V Almeida; Paul J Converse; Si-Yang Li; Sandeep Tyagi; Eric L Nuermberger; Jacques H Grosset
Journal:  PLoS Negl Trop Dis       Date:  2013-02-28

5.  Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.

Authors:  Aurélie Chauffour; Jérôme Robert; Nicolas Veziris; Alexandra Aubry; Vincent Jarlier
Journal:  PLoS Negl Trop Dis       Date:  2016-10-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.